Modimelanotide

Modimelanotide
Clinical data
Other names	Acetylhexa-L-lysyl-α-MSH; AP-214; ABT-719; ZP-1480
ATC code	None;
Identifiers
	IUPAC name N2-acetyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-seryl-L-tyrosyl-L-seryl-L-methionyl-L-alpha-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-L-valinamide;
CAS Number	926277-68-1;
PubChem CID	72941953;
ChemSpider	34988374;
UNII	96C1EBE9CG;
CompTox Dashboard (EPA)	DTXSID001032325 ;
Chemical and physical data
Formula	C113H181N33O25S
Molar mass	2433.96 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [H]/N=C(\N)/NCCC[C@@H](C(=O)N[C@@H](Cc1c[nH]c2c1cccc2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc5c[nH]cn5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](Cc6ccc(cc6)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)C;
	InChI InChI=1S/C113H181N33O25S/c1-66(2)94(95(121)154)145-111(170)91-38-25-54-146(91)112(171)84(36-16-23-52-120)130-92(151)62-127-96(155)87(58-70-60-126-74-29-9-8-28-73(70)74)141-102(161)81(37-24-53-125-113(122)123)136-106(165)85(56-68-26-6-5-7-27-68)139-108(167)88(59-71-61-124-65-128-71)142-104(163)82(43-44-93(152)153)137-105(164)83(45-55-172-4)138-109(168)89(63-147)144-107(166)86(57-69-39-41-72(150)42-40-69)140-110(169)90(64-148)143-103(162)80(35-15-22-51-119)135-101(160)79(34-14-21-50-118)134-100(159)78(33-13-20-49-117)133-99(158)77(32-12-19-48-116)132-98(157)76(31-11-18-47-115)131-97(156)75(129-67(3)149)30-10-17-46-114/h5-9,26-29,39-42,60-61,65-66,75-91,94,126,147-148,150H,10-25,30-38,43-59,62-64,114-120H2,1-4H3,(H2,121,154)(H,124,128)(H,127,155)(H,129,149)(H,130,151)(H,131,156)(H,132,157)(H,133,158)(H,134,159)(H,135,160)(H,136,165)(H,137,164)(H,138,168)(H,139,167)(H,140,169)(H,141,161)(H,142,163)(H,143,162)(H,144,166)(H,145,170)(H,152,153)(H4,122,123,125)/t75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,94-/m0/s1; Key:WHRVKPBBRZHWTN-ZHHKRVSMSA-N;

Modimelanotide (INN; development code AP-214, ABT-719, and ZP-1480) is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development by, at different times, Action Pharma, Abbott Laboratories, AbbVie, and Zealand for the treatment of acute kidney injury.^[1]^[2] It acts as a non-selective melanocortin receptor agonist, with IC₅₀ values of 2.9 nM, 1.9 nM, 3.7 nM, and 110 nM at the MC₁, MC₃, MC₄, and MC₅ receptors.^[3] Modimelanotide failed clinical trials for acute kidney injury despite showing efficacy in animal models,^[4]^[5] and development was not further pursued.^[1]^[2]

References

^ ^a ^b Ramos AM, González-Guerrero C, Sanz A, Sanchez-Niño MD, Rodríguez-Osorio L, Martín-Cleary C, et al. (May 2015). "Designing drugs that combat kidney damage". Expert Opinion on Drug Discovery. 10 (5): 541–56. doi:10.1517/17460441.2015.1033394. PMID 25840605. S2CID 24191324.
^ ^a ^b Montero-Melendez T (May 2015). "ACTH: The forgotten therapy". Seminars in Immunology. 27 (3): 216–26. doi:10.1016/j.smim.2015.02.003. PMID 25726511.
^ "Renal-Urologic drugs". Drug Data Reports. 29 (1). Prous Science: 42. 2007. ISSN 0379-4121.
^ Doi K, Hu X, Yuen PS, Leelahavanichkul A, Yasuda H, Kim SM, et al. (June 2008). "AP214, an analogue of alpha-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality". Kidney International. 73 (11): 1266–74. doi:10.1038/ki.2008.97. PMC 2398767. PMID 18354376.
^ Simmons MN, Subramanian V, Crouzet S, Haber GP, Colombo JR, Ukimura O, et al. (April 2010). "Alpha-melanocyte stimulating hormone analogue AP214 protects against ischemia induced acute kidney injury in a porcine surgical model". The Journal of Urology. 183 (4): 1625–9. doi:10.1016/j.juro.2009.12.007. PMID 20172543.

External links

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

[RamosGonzález-Guerrero2015-1] Ramos AM, González-Guerrero C, Sanz A, Sanchez-Niño MD, Rodríguez-Osorio L, Martín-Cleary C, et al. (May 2015). "Designing drugs that combat kidney damage". Expert Opinion on Drug Discovery. 10 (5): 541–56. doi:10.1517/17460441.2015.1033394. PMID 25840605. S2CID 24191324.

[Montero-Melendez2015-2] Montero-Melendez T (May 2015). "ACTH: The forgotten therapy". Seminars in Immunology. 27 (3): 216–26. doi:10.1016/j.smim.2015.02.003. PMID 25726511.

[issn0379-4121-3] "Renal-Urologic drugs". Drug Data Reports. 29 (1). Prous Science: 42. 2007. ISSN 0379-4121.

[DoiHu2008-4] Doi K, Hu X, Yuen PS, Leelahavanichkul A, Yasuda H, Kim SM, et al. (June 2008). "AP214, an analogue of alpha-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality". Kidney International. 73 (11): 1266–74. doi:10.1038/ki.2008.97. PMC 2398767. PMID 18354376.

[SimmonsSubramanian2010-5] Simmons MN, Subramanian V, Crouzet S, Haber GP, Colombo JR, Ukimura O, et al. (April 2010). "Alpha-melanocyte stimulating hormone analogue AP214 protects against ischemia induced acute kidney injury in a porcine surgical model". The Journal of Urology. 183 (4): 1625–9. doi:10.1016/j.juro.2009.12.007. PMID 20172543.

[1]

[2]

[3]

[4]

[5]

v t e Melanocortin receptor modulators
MC₁	Agonists: ACTH (corticotropin) Afamelanotide (melanotan I) BMS-470539 Bremelanotide HS-014 HS-024 MSH (α, β, γ) Melanotan II Modimelanotide PL-8177 SHU-8914 SHU-9005 SHU-9119 SNAP-7941 Antagonists: ASIP
MC₂	Agonists: ACTH (corticotropin) Alsactide Codactide Giractide Norleusactide (pentacosactride) Seractide Tetracosactide (tetracosactrin, cosyntropin) Tosactide (octacosactrin) Tricosactide Tridecactide Antagonists: Atumelnant (CRN04894)
MC₃	Agonists: ACTH (corticotropin) Afamelanotide (melanotan I) Bremelanotide MSH (α, β, γ) Melanotan II Modimelanotide PG-931 Antagonists: AGRP ASIP HS-014 Mifomelatide (TCMCB07) ML-00253764 PG-106 SHU-8914 SHU-9005 SHU-9119
MC₄	Agonists: ACTH (corticotropin) Afamelanotide (melanotan I) AZD2820 BIM-22493 Bivamelagon (LB54640) Bremelanotide LY-2112688 MSH (α, β, γ) Melanotan II MK-0493 Modimelanotide PF-00446687 PG-931 PL-6983 Ro 27-3225 Setmelanotide THIQ Antagonists: AGRP ASIP HS-014 HS-024 HS-131 JKC-363 MCL-0020 MCL-0042 MCL-0129 ML-00253764 MPB-10 SHU-8914 SHU-9005 SHU-9119 Unknown: Semax
MC₅	Agonists: ACTH (corticotropin) Afamelanotide (melanotan I) Bremelanotide HS-014 HS-024 MSH (α, β, γ) Melanotan II Modimelanotide SHU-8914 SHU-9005 SHU-9119 Antagonists: ASIP ML-00253764 Unknown: Semax
Unsorted	Agonists: Alsactide Codactide Dersimelagon Giractide Norleusactide (pentacosactride) Seractide Tetracosactide (tetracosactrin, cosyntropin) Tosactide (octacosactrin) Tricosactide Tridecactide
Others	Propeptides: Lipotropin (β, γ) N-POMC (NPP, pro-γ-MSH) Proopiomelanocortin (POMC)

Modimelanotide

Hub talks

Modimelanotide

Modimelanotide

Hub rules

Modimelanotide

Hub overview

Add your contribution

Inside this hub

Media Collections

Timelines

Articles

Notes collections

Notes

Days in Chronicle

Root Wikipedia Article

Modimelanotide

See also

References

External links

Add your contribution

Related Hubs